Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Visual outcomes of moderate monovision with monofocal IOLs vs a small-aperture IOL

Poster Details

First Author: B.Soares AUSTRALIA

Co Author(s):    J. Beltz                    

Abstract Details


To evaluate range of vision and patient satisfaction with modified monovision with bilateral aspheric monofocal IOLs versus contralateral implantation of a monofocal IOL and a small-aperture extended depth of focus IOL.


Prospective, post-market, single site randomised controlled trial. Surgeries performed at the Royal Victorian Eye and Ear Hospital in Melbourne, Australia.


Forty subjects randomized into 2 groups. Group 1 implanted bilaterally with aspheric monofocal IOLs with refractive targets of emmetropia and -1.25 D in dominant and non-dominant eyes, respectively. Group 2 received an aspheric monofocal IOL in the dominant eye targeting emmetropia and an IC-8 IOL in the non-dominant eye targeting for -0.75 D. Nine subjects enrolled to date. One month monocular and binocular (OU) uncorrected near, intermediate and distance visual acuity (UCNVA, UCIVA, UCDVA) outcomes for 2 subjects per group are presented here. Results reported in decimal. Additional patients, follow-up visits and satisfaction results to be presented.


Mean monocular UCDVA was 0.6 + 0.28 for the IC-8 IOL eyes and 0.53 + 0.39 for the monofocal near eye. For UCIVA, IC-8 IOL eyes and near monofocal IOL eyes were 0.75 + 0.35 and 0.9 + 0.14, respectively. UCNVA for IC-8 IOL eyes was 0.82 + 0.26 and 0.52 + 0.16 in near monofocal IOL eyes. Binocularly, the monofocal subjects achieved 1.0 + 0.0, 0.9 + 0.14 and 0.52 + 0.16 for UCDVA, UCIVA and UCNVA. IC-8 IOL patients achieved 1.0 + 0.0 UCDVA OU, 0.75 + 0.35 UCIVA OU and 0.82 + 0.26 UCNVA OU.


Interim results appear to be comparable between groups. Additional patients and follow-up is required.

Financial Disclosure:


Back to Poster listing